Introduction:
GPT Healthcare Ltd., renowned for its ILS hospitals, stands out as a prominent player in the regional corporate healthcare sector. With a robust presence across four mid-sized full-service hospitals in West Bengal and Tripura, specializing in secondary and tertiary care services, the company embarks on a transformative journey with the opening of its Initial Public Offering (IPO) on Thursday, February 22.
GPT Healthcare IPO GMP:
The Grey Market Premium (GMP) serves as a vital indicator, offering insights into investor sentiment ahead of the subscription phase. As the unlisted market indicates, GPT Healthcare’s shares are trading at par with their issue price, signaling equilibrium in the pre-subscription phase. Investors keenly monitor the GMP to gauge potential listing prices, underscoring the anticipation surrounding the IPO.
Issue Details:
The IPO, slated to close on February 26, presents a compelling opportunity for investors with a price band fixed between ₹177 to ₹186 per share. Investors can participate with a minimum bid of 80 equity shares in one lot, with allocations tailored for various investor categories. Notably, the IPO comprises a blend of fresh equity issuance and an offer for sale (OFS), facilitating the exit of BanyanTree Growth Capital II from its stake in GPT Healthcare.
Company Overview:
Founded in 2000 by Dwarika Prasad Tantia, Dr. Om Tantia, and Shree Gopal Tantia, GPT Healthcare has evolved from its humble beginnings with an eight-bed hospital in Kolkata to managing four full-service multi-specialty hospitals under the ILS Hospitals brand. As of September 30, 2023, ILS Hospitals cater to diverse medical needs across Dum Dum, Salt Lake, Howrah, and Agartala, offering integrated healthcare across 35 specialties and super specialties.
Financial Performance:
In a competitive arena, GPT Healthcare competes with listed industry peers, showcasing its resilience and growth potential. Financially, the company has demonstrated commendable performance, with a notable CAGR of 36% in net profit and 20.53% in EBITDA for FY23. This momentum persisted into the first half of FY24, with a year-on-year increase of 38% in net profit and 18.7% in revenue.
Conclusion:
As GPT Healthcare embarks on its IPO journey, it symbolizes a pivotal moment for the company, reflecting its commitment to excellence and growth. With a compelling value proposition and promising financial performance, the IPO presents an attractive opportunity for investors seeking exposure to the dynamic healthcare sector. As the subscription phase unfolds, all eyes remain on GPT Healthcare’s trajectory, poised for a transformative listing experience.
Disclaimer:
This article provides insights and analysis regarding GPT Healthcare’s IPO and its implications. Readers are encouraged to conduct thorough due diligence and consult financial advisors before making any investment decisions.
